Asepha, a rapidly growing startup using AI agents for pharmacy automation, has closed a $4 million seed funding round. The round was led by Glasswing Ventures and Core Innovation Capital, with participation from Panache, RedBud, MGV, and follow-on support from Ripple Ventures and Front Row Ventures.
Founded in 2023 by Eunice Wu and Can Uncu, Asepha aims to solve critical bottlenecks in pharmacy care. With approximately 70% of pharmacies understaffed and pharmacists spending up to 90% of their time on administrative tasks, Asepha offers a suite of interoperable AI agents to streamline operations, accelerate workflows, and boost accuracy.
Asepha’s tools include an OCR prescription entry agent that processes complex, handwritten prescriptions with 96% accuracy, significantly reducing manual data entry. A call agent automates up to 70% of inbound phone calls, freeing up staff, while a browser navigation agent handles real-time web-based administrative tasks. Validation experiments showed pharmacists preferred Asepha’s AI responses over human responses 71% of the time in a double-blinded trial.
This new funding will enable Asepha to expand its engineering and go-to-market teams, grow global partnerships, and establish a U.S. presence with a new office in New York City. The company has already secured multiple Fortune 50 enterprise customers.
KEY QUOTES:
“As a pharmacist, I experienced firsthand how much of our time is consumed by manual tasks that pull us away from patient needs. Asepha allows care teams to focus on what matters most, the people we serve. This funding allows us to scale that vision and bring meaningful relief to an overstretched workforce. Our products are moving the needle in one of healthcare’s most operationally complex environments, improving access for tens of millions of patients along the way.”
Eunice Wu, CEO and Co-Founder of Asepha; Wu is a Doctor of Pharmacy with experience working in various hospitals and retail pharmacies across Canada.
“AI is fundamentally restructuring industry workflows. We’re building the safety infrastructure and validation frameworks necessary for responsible pharmaceutical AI deployment through strategic research collaborations.”
Can Uncu, CTO and Co-Founder; Uncu previously worked at AMD on the MI300X chip, which powers OpenAI and Microsoft Azure today.
“Eunice and Can recognize the transformative power AI Agents will have on verticalized industries such as pharmaceuticals. By building an agentic API that does not require learning new interfaces or workflows, Asepha circumvents the common hurdles when introducing traditional software technology to highly regulated industries, while powering frictionless adoption. We are excited to be leading this financing round and to partner with Asepha as it drives efficiency gains without disruption.”
Rudina Seseri, Founder and Managing Partner at Glasswing Ventures
“Asepha reflects two key theses we believe in. First, the companies most likely to find early success in today’s market will start with a tightly focused wedge that is both verticalized and use-case specific, rather than trying to serve everyone or everything from the outset. Second, some of the earliest and most scalable wins will come where technology aligns with macro and demographic trends. In Asepha’s case, they are helping to fill the massive supply-demand gap in pharmacy labor. That alignment not only creates real urgency, but also makes the go-to-market motion far more natural.”
Edwin Loredo, Partner at Core Innovation Capital
